Overview Dividends

(CYRX) Cryoport - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2290503075

Cryogenic Shippers, Freezers, Bioservices, Monitoring, Logistics

CYRX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 7.41%
EPS Trend (3Y Correlation): 43.3%

CYRX Revenue

Revenue Growth (3Y CAGR): -9.86%
Revenue Trend (3Y Correlation): -65.6%

Description: CYRX Cryoport October 26, 2025

Cryoport, Inc. (NASDAQ:CYRX) delivers temperature-controlled supply-chain solutions across biopharma, animal health, and reproductive-medicine markets. Its business is split between a Life Sciences Services segment-offering logistics, cryogenic biostorage, and end-to-end sample-management-and a Life Sciences Products segment, which sells cryogenic freezers, dewars, and related accessories through direct sales and distributors.

Key operating metrics (FY 2023) show revenue of roughly $140 million, up about 10 % year-over-year, with an adjusted EBITDA margin near 12 %. The company’s growth is closely tied to the rapid expansion of cell-and-gene-therapy pipelines, which demand ultra-cold logistics, and to the broader biologics market that is projected to exceed $400 billion by 2028. Cryoport’s recent multi-year contracts to support COVID-19 vaccine distribution and emerging mRNA therapeutics illustrate its positioning within this high-growth cold-chain niche.

Given Cryoport’s niche focus and the accelerating demand for reliable cryogenic infrastructure, a deeper quantitative dive-such as the one available on ValueRay-can help you assess valuation multiples, peer benchmarks, and scenario-based cash-flow projections.

CYRX Stock Overview

Market Cap in USD	463m
Sub-Industry	Health Care Equipment
IPO / Inception	2005-03-15

CYRX Stock Ratings

Growth Rating	-30.2%
Fundamental	22.0%
Dividend Rating	-
Return 12m vs S&P 500	-12.0%
Analyst Rating	4.0 of 5

CYRX Dividends

Currently no dividends paid

CYRX Growth Ratios

Growth Correlation 3m	57.9%
Growth Correlation 12m	44.3%
Growth Correlation 5y	-94%
CAGR 5y	-18.78%
CAGR/Max DD 3y (Calmar Ratio)	-0.23
CAGR/Mean DD 3y (Pain Ratio)	-0.37
Sharpe Ratio 12m	-1.51
Alpha	-10.52
Beta	1.611
Volatility	81.02%
Current Volume	1514.6k
Average Volume 20d	631.2k
Stop Loss	7.9 (-7.4%)
Signal	0.63

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (75.3m TTM) > 0 and > 6% of Revenue (6% = 12.2m TTM)

FCFTA -0.04 (>2.0%) and ΔFCFTA 0.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 226.6% (prev 212.8%; Δ 13.79pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.02 (>3.0%) and CFO -16.7m <= Net Income 75.3m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 16.24 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (50.1m) change vs 12m ago 1.53% (target <= -2.0% for YES)

Gross Margin 45.73% (prev 46.97%; Δ -1.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 24.93% (prev 24.37%; Δ 0.56pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -12.91 (EBITDA TTM -5.56m / Interest Expense TTM 2.73m) >= 6 (WARN >= 3)

Altman Z'' -1.95

(A) 0.59 = (Total Current Assets 489.5m - Total Current Liabilities 30.1m) / Total Assets 773.9m

(B) -0.86 = Retained Earnings (Balance) -668.2m / Total Assets 773.9m

(D) -2.61 = Book Value of Equity -673.6m / Total Liabilities 258.5m

Total Rating: -1.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 22.01

1. Piotroski 1.0pt = -4.0

2. FCF Yield -12.87% = -5.0

3. FCF Margin -16.84% = -6.32

4. Debt/Equity 0.44 = 2.40

5. Debt/Ebitda 2.68 = -1.27

6. ROIC - WACC (= -14.14)% = -12.50

7. RoE 17.37% = 1.45

8. Rev. Trend -65.58% = -4.92

9. EPS Trend 43.35% = 2.17

What is the price of CYRX shares?

As of November 06, 2025, the stock is trading at USD 8.53 with a total of 1,514,569 shares traded.
Over the past week, the price has changed by -7.68%, over one month by -14.53%, over three months by +26.56% and over the past year by +4.66%.

Is Cryoport a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Cryoport (NASDAQ:CYRX) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 22.01 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CYRX is around 7.36 USD . This means that CYRX is currently overvalued and has a potential downside of -13.72%.

Is CYRX a buy, sell or hold?

Cryoport has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CYRX.

Strong Buy: 4
Buy: 2
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CYRX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	12.8	49.8%
Analysts Target Price	12.8	49.8%
ValueRay Target Price	8.2	-4.2%

CYRX Fundamental Data Overview November 03, 2025

Market Cap USD = 462.6m (462.6m USD * 1.0 USD.USD)
P/E Forward = 58.1395
P/S = 1.9448
P/B = 0.9822
Beta = 1.611
Revenue TTM = 202.7m USD
EBIT TTM = -35.2m USD
EBITDA TTM = -5.56m USD
Long Term Debt = 185.8m USD (from longTermDebt, last quarter)
Short Term Debt = 8.63m USD (from shortTermDebt, last quarter)
Debt = 228.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -14.9m USD (from netDebt column, last quarter)
Enterprise Value = 265.2m USD (462.6m + Debt 228.5m - CCE 426.0m)
Interest Coverage Ratio = -12.91 (Ebit TTM -35.2m / Interest Expense TTM 2.73m)
FCF Yield = -12.87% (FCF TTM -34.1m / Enterprise Value 265.2m)
FCF Margin = -16.84% (FCF TTM -34.1m / Revenue TTM 202.7m)
Net Margin = 37.16% (Net Income TTM 75.3m / Revenue TTM 202.7m)
Gross Margin = 45.73% ((Revenue TTM 202.7m - Cost of Revenue TTM 110.0m) / Revenue TTM)
Gross Margin QoQ = 47.03% (prev 45.42%)
Tobins Q-Ratio = 0.34 (Enterprise Value 265.2m / Total Assets 773.9m)
Interest Expense / Debt = 0.27% (Interest Expense 618.0k / Debt 228.5m)
Taxrate = -2.30% (negative due to tax credits) (274.0k / -11.9m)
NOPAT = -36.0m (EBIT -35.2m * (1 - -2.30%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 16.24 (Total Current Assets 489.5m / Total Current Liabilities 30.1m)
Debt / Equity = 0.44 (Debt 228.5m / totalStockholderEquity, last quarter 515.4m)
Debt / EBITDA = 2.68 (negative EBITDA) (Net Debt -14.9m / EBITDA -5.56m)
Debt / FCF = 0.44 (negative FCF - burning cash) (Net Debt -14.9m / FCF TTM -34.1m)
Total Stockholder Equity = 433.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.73% (Net Income 75.3m / Total Assets 773.9m)
RoE = 17.37% (Net Income TTM 75.3m / Total Stockholder Equity 433.7m)
RoCE = -5.68% (EBIT -35.2m / Capital Employed (Equity 433.7m + L.T.Debt 185.8m))
RoIC = -6.05% (negative operating profit) (NOPAT -36.0m / Invested Capital 594.5m)
WACC = 8.09% (E(462.6m)/V(691.1m) * Re(11.95%) + D(228.5m)/V(691.1m) * Rd(0.27%) * (1-Tc(-0.02)))
Discount Rate = 11.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.16%
Fair Price DCF = unknown (Cash Flow -34.1m)
EPS Correlation: 43.35 | EPS CAGR: 7.41% | SUE: 0.25 | # QB: 0
Revenue Correlation: -65.58 | Revenue CAGR: -9.86% | SUE: 0.61 | # QB: 0

Additional Sources for CYRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle